Apricus Biosciences

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has initiated a Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions. Apricus recently completed enrollment in a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon. Apricus’ lead commercial product, Vitaros®, for the treatment of ED, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus’ marketing partners for Vitaros include Mylan NV, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Apricus’ second-generation room temperature Vitaros is under development. Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the Nasdaq Capital Market under the ticker symbol APRI.
Company Growth (employees)
San Diego, US
Size (employees)
24 (est)
Apricus Biosciences is headquartered in San Diego, US

Apricus Biosciences Office Locations

Apricus Biosciences has an office in San Diego
San Diego, US (HQ)
300 11975 El Camino Real

Apricus Biosciences Data and Metrics

Apricus Biosciences Financial Metrics

Apricus Biosciences's revenue was reported to be $5.8 m in 2016
Numbers are in $, USD

Revenue (Y, 2016)

5.8 m

Revenue growth (Y, 2015 - Y, 2016), %


Gross profit (Y, 2016)

5.3 m

Gross profit margin (Y, 2016), %


Net income (Y, 2016)

(7.4 m)

Market capitalization (26-May-2017)

7.4 m

Closing share price (26-May-2017)


Cash (31-Dec-2016)

2.1 m
Apricus Biosciences's current market capitalization is $7.4 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015Y, 2016


2.5 m9.3 m4.8 m5.8 m

Revenue growth, %


Cost of goods sold

23 k918 k922 k511 k

Gross profit

2.5 m8.3 m3.9 m5.3 m

Gross profit Margin, %


Operating expense total

17.2 m30.9 m25.3 m15.3 m


(17.4 m)(22.6 m)(21.4 m)

EBIT margin, %


Interest expense

727 k339 k845 k1 m

Income tax expense

Net Income

(16.9 m)(21.8 m)(19 m)(7.4 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


21.4 m11.4 m3.9 m2.1 m

Accounts Receivable

59 k678 k519 k530 k


336 k275 k469 k764 k

Current Assets

22.3 m13.3 m6.3 m3.6 m


955 k1.4 m1.3 m1 m

Total Assets

23.3 m14.8 m7.9 m4.7 m

Accounts Payable

926 k860 k1.6 m960 k

Total Debt

306 k

Current Liabilities

11.8 m6.9 m15.8 m11.3 m

Additional Paid-in Capital

279 m291.7 m298.9 m308.8 m

Retained Earnings

(268.1 m)(289.9 m)(308.9 m)(316.3 m)

Debt to Assets Ratio

0 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(16.9 m)(21.8 m)(19 m)(7.4 m)

Depreciation and Amortization

77 k170 k300 k289 k

Accounts Receivable

253 k(620 k)159 k(11 k)


(341 k)61 k(194 k)(295 k)

Accounts Payable

(920 k)(66 k)609 k(509 k)

Cash From Operating Activities

6.3 m(10 m)(7.5 m)(13.1 m)

Purchases of PP&E

(573 k)(580 k)(337 k)

Cash From Investing Activities

265 k

Cash From Financing Activities

11 m

Interest Paid

238 k193 k538 k646 k

Income Taxes Paid

6 k

Apricus Biosciences Market Value History

Apricus Biosciences Online and Social Media Presence

Apricus Biosciences News and Updates

Apricus Biosciences Company Life and Culture

You may also be interested in